{"id":"NCT01476787","sponsor":"Celgene","briefTitle":"Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma","officialTitle":"A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-12-29","primaryCompletion":"2024-04-30","completion":"2024-04-30","firstPosted":"2011-11-22","resultsPosted":"2025-05-14","lastUpdate":"2025-05-14"},"enrollment":1030,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Follicular Lymphoma"],"interventions":[{"type":"DRUG","name":"Rituximab","otherNames":[]},{"type":"DRUG","name":"Lenalidomide","otherNames":["Revlimid"]},{"type":"DRUG","name":"Rituximab-CHOP","otherNames":[]},{"type":"DRUG","name":"Rituximab-CVP","otherNames":[]},{"type":"DRUG","name":"Rituximab-Bendamustine","otherNames":[]}],"arms":[{"label":"Lenalidomide + Rituximab","type":"EXPERIMENTAL"},{"label":"Control","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the effect of the combined treatment of lenalidomide and rituximab in controlling the Follicular Lymphoma disease and also increase the length of response compared to the available standard combination chemotherapy treatment for Follicular Lymphoma.","primaryOutcome":{"measure":"Complete Response Rate (CR/CRu) at 120 Weeks by Independent Central Review","timeFrame":"At 120 weeks","effectByArm":[{"arm":"Rituximab-Lenalidomide","deltaMin":48.1,"sd":null},{"arm":"Investigator Choice","deltaMin":53,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.128"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":10},"locations":{"siteCount":36,"countries":["United States","Japan"]},"refs":{"pmids":["30184451","25439689","24122387","32673385","39374535"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsclinicaltrials.com/us/en/home"]},"adverseEventsSummary":{"seriousAny":{"events":181,"n":507},"commonTop":["NEUTROPENIA","CONSTIPATION","NAUSEA","ASTHENIA","DIARRHOEA"]}}